Health · Medical Research · 10 hrs ago
Tumor imaging index may predict response to breast cancer drugs
Researchers at Hong Kong Polytechnic University developed an imaging measure called the Tumour Heterogeneity Index, or THI.
It is designed to assess how breast cancer patients may respond to AKT inhibitors before they start treatment.
The approach uses imaging, so the assessment is noninvasive.
In the study, patients with a high THI had an estimated 56.1% rate of pathological complete response, meaning no cancer was found in tissue examined after treatment.
The study found this rate was significantly higher than for patients with a low THI.
The index could help clinicians choose suitable treatment earlier, but the information provided does not say what happens next.
Researchers at The Hong Kong Polytechnic University developed an imaging biomarker called the Tumour Heterogeneity Index (THI).
THI can noninvasively assess breast cancer patients’ response to AKT inhibitors before treatment.
The study found an estimated pathological complete response rate of 56.1% among patients with a high THI.
That rate was significantly higher than the rate among patients with a low THI.
The researchers said the technology could help clinicians identify patients most likely to benefit from therapy.
- Who
- Researchers at The Hong Kong Polytechnic University developed the index.
- What
- They developed an imaging biomarker to assess breast cancer patients’ response to AKT inhibitors.
- When
- Not stated
- Where
- The Hong Kong Polytechnic University.
- Why
- To help clinicians identify patients most likely to benefit from therapy before treatment.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Index
- Tumour Heterogeneity Index (THI)
- Developer
- The Hong Kong Polytechnic University
- Drug class
- AKT inhibitors
- High-THI group
- Estimated pathological complete response rate of 56.1%